A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: f901d45d287562bcf576dad34d745e98371774bf
First added on: Mar 21, 2025